Sideeffects

TKI class/molecule

Percentage (%)

Skin involvement

Rash

Anti-EGFR

27.5 (G1, G2), 22.5 (G3, G4)

Anti-VEGFR

29.5 (G1, G2)

c-Kitinhibitors(imatinib)

11 (G1, G2)

Hand-foot syndrome

Anti-EGFR

17.5 (G1, G2)

Anti-VEGFR

52.5 (G1, G2), 7 (G3, G4)

c-Kitinhibitors(imatinib)

0

Xerosis

Anti-EGFR

35 (G1, G2)

Anti-VEGFR

25 (G1, G2)

c-Kitinhibitors(imatinib)

17 (G1, G2)

Yellowish discoloration of the skin

Skin depigmentation

Sunitinib

14

Imatinib

12.5

Hair damage

Alopecia

Anti-EGFR

37.5

Anti-VEGFR

65

c-Kitinhibitors(imatinib)

35

Texture modification

Anti-EGFR

45

Anti-VEGFR

82

c-Kitinhibitors(imatinib)

0

Depigmentation

Sunitinib

7

Nailinvolvement

Paronychia

Anti-EGFR

52.5

Subungualhaemorrhages

Anti-VEGFR

43.7

Digestive damage

Diarrhea

Anti-EGFR

47.5 (G1, G2), 15 (G3)

Anti-VEGFR

32 (G1, G2), 4.5 (G3)

c-Kitinhibitors(imatinib)

22

Nausea/vomiting

Anti-EGFR

37.5 (G1, G2)

Anti-VEGFR

28.5 (G1, G2), 5.5 (G3)

c-Kitinhibitors(imatinib)

34.7 (G1, G2)

Stomatitis

Anti-EGFR

55 (G1, G2)

Anti-VEGFR

37.5 (G1, G2), 2 (G3, G4)

c-Kitinhibitors(imatinib)

1.5 (G1, G2)

Hematologicinvolvement

Anemia

Anti-EGFR

30 (G1, G2)

Anti-VEGFR

35 (G1, G2), 1.8 (G3, G4)

c-Kitinhibitors(imatinib)

24 (G1, G2), 2.7 (G3, G4)

Thrombocytopenia

Anti-EGFR

20 (G1, G2)

Anti-VEGFR

18 (G1, G2), 4.5 (G3, G4)

c-Kitinhibitors(imatinib)

12.5 (G1, G2)